M&A Deal Summary

Forte Biosciences Acquires Tocagen

On June 15, 2020, Forte Biosciences acquired life science company Tocagen

Acquisition Highlights
  • This is Forte Biosciences’ 1st transaction in the Life Science sector.
  • This is Forte Biosciences’ 1st transaction in the United States.
  • This is Forte Biosciences’ 1st transaction in California.

M&A Deal Summary

Date 2020-06-15
Target Tocagen
Sector Life Science
Buyer(s) Forte Biosciences
Deal Type Merger
Advisor(s) Ladenburg Thalmann & Co. (Financial)
Cooley (Legal)

Target

Tocagen

San Diego, California, United States
Tocagen is a fully integrated global biotech company that develops first-in-class, broadly applicable, product candidates, that are designed to activate a patient’s immune system against their own cancer from within. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. Tocagen was formed in 2007 and is based in San Diego, California.

Search 214,600 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Forte Biosciences

Torrance, California, United States

Category Company
Founded 2007
Sector Life Science
Employees11
Revenue 32M USD (2023)
DESCRIPTION

Forte Biosciences is a clinical-stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric (3 years of age and older) patients with atopic dermatitis. Forte Biosciences was incorporated in 2007 and is based in Torrance, California.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Merger M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2020 M&A 1 of 1